Patrick Heron

Frazier Life Sciences invests globally in private and publicly-traded companies that discover and commercialize biopharmaceuticals.

HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.

Raised $235,000,000.00 from Deerfield, Abingworth, Greenspring Associates, RA Capital Management, Catalys Pacific, Richard King Mellon Foundation, Qiming Venture Partners USA, Perceptive Advisors, Biotechnology Value Fund and Lightspeed Venture Partners.

MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.

Raised $238,400,000.00 from OrbiMed, New Enterprise Associates, Wellington Management, Frazier Life Sciences, Norwest Venture Partners, Deep Track Capital, Driehaus Capital Management, T. Rowe Price and RA Capital Management.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.

Raised $833,500,000.00 from SLR Capital Partners.

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.

Raised $497,000,000.00 from Oberland Capital.

Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies.

Raised $272,000,000.00 from California Institute for Regenerative Medicine.